Granisetron plus dexamethasone

PreclinicalSmall molecule

Granisetron plus dexamethasone is one of 12 small molecule programs targeting Chemotherapy-induced nausea and vomiting. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chemotherapy-Induced Nausea and VomitingActive, not recruiting

Chemotherapy-Induced Nausea and VomitingPreclinical

Active, not recruiting

Competition

Competitive Landscape

11 competitors in Chemotherapy-Induced Nausea and Vomiting

#DrugCompanyPhaseTrials

Zofran

Novartis

Approved

7 2

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Approved

7 3

Decadron

AAspen Global Incorporated

Approved

6 4

Avelox

Bayer

Approved

—5

Aspercreme Warming

AAveritas Pharma, Inc.

Remeron

Barhemsys

Tibotec Pharmaceuticals, Ireland

Depo-Provera

1 9

HSK21542

Haisco Pharmaceutical Group Co., Ltd.

Phase 2

1 10

Ramosetron

Astellas

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chemotherapy-induced nausea and vomiting1 trial

Comparative Study of Fosaprepitant and Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Pediatric Caner Patients

Unknown status·SShanghai Children's Medical Center·N/A·NCT04873284·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Granisetron plus dexamethasone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Granisetron plus dexamethasone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Granisetron plus dexamethasone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Children's Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SShanghai Children's Medical Center

Granisetron plus dexamethasone

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Chemotherapy-induced nausea and vomiting1 trial

References

Drug Info

Quick Facts

Related News